
Markets for technology and the division of innovative labor: A view from the ivory tower

Ashish Arora Heinz School, Carnegie Mellon Fuqua School, Duke University And National Bureau of Economic Research

Evolution of Innovation Models

- <u>Early in the 20th century:</u> modern industrial enterprises internalized the R&D function
- <u>End of 20th Century</u> : Greater dependence on outside sources of innovation
 - Licensing
 - alliances
 - "open innovation"
- True? If so, why?

Back to the future?



Estimates of technology licensing in the US, 2002 (IRS + BEA data)

Distribution of IRS Receipts for Types of IP-Licensing Service Commodities across Industry Sectors, 2002, Billions of Dollars

Sector	Licensing of Rights to Use IP Protected as Industrial Property	Licensing of rights to use IP protected by t rademarks	Licensing of rights to use IP protected by Copyright	Licensing of Rights to use a business format under a franchise	Payments for rights to use Natural Resources and Other intangibles	Total
Manufacturing	59.5	9.4	1.0	2.9	-	72.8
Distributive Services	1.0	6.9	0.1	5.1	-	13.1
Information	1.9	4.9	6.6	0.0	0.1	13.5
Finance and Insurance	0.2	0.7	0.0	1.4	0.0	2.4
Professional and Business Services	3.0	0.2	1.6	1.5	0.4	6.7
Other Industries	1.0	0.7	0.1	4.8	0.8	7.5
Total	66.6	22.8	9.4	15.7	1.3	115.9



Carol Robbins, Dept. of Commerce, 2006, tab 7



Patents and market for technology: Patents promote licensing by small firms

	<u>Small</u> <u>Firm</u>	<u>Large</u> <u>Firm</u>
% increase in licensing propensity	6%	2%
% increase in the propensity to license patented innovations	1%	-3%

Source: Arora and Ceccagnoli, "Patenting and licensing", 2005

Patents promote entry of specialized tech suppliers in chemicals

Ţ




Implications of markets for technology

Information security software: non-producer patents, licensing, entry and exit are correlated


- Encryption markets
 - More patent intensive (Giarratana, 2004)

The market for technology in bio-pharma is significant



Pharma firms rely extensively on outside knowledge for their products.

Percent of new drugs with more than 50% of patent attached to the drug being not held by the commercializing firm, for companies with >10 NDAs --> 1989-2004



Markets for technology and their discontents

Whither bio-pharma? Patenting and academic research? Anti-commons?


Foundational patents: university patents may be as guilty as others in blocking research



Source: National Academy of Sciences, 2005

"WE HAVE MET THE ENEMY AND HE IS US"

Thickets and patent fragmentation



- Patent landscape becoming more complex
- <u>Substantial litigation costs</u> (and perhaps rising) (e.g., Lanjouw and Schankerman, 2003)
- Potential for harm exists limited evidence as yet.

Anti-commons: An uncommon tragedy?

Patents as potential roadblocks

- Bad patents create problems.
- Bad patents in the hands of players with short term strategies create bigger problems – BUT
- Patent policy must not discriminate against business models based on licensing.
- In a knowledge based economy, prejudices in favor of material production is simply a prejudice. SO
- Investing in improving the quality of patents is a good idea.
- Getting the USPTO to recognize that its mission is not to serve inventors but to serve society.